185 related articles for article (PubMed ID: 8625402)
1. Die and let live: eliminating dangerous lymphocytes.
Abbas AK
Cell; 1996 Mar; 84(5):655-7. PubMed ID: 8625402
[No Abstract] [Full Text] [Related]
2. Functional Fas and Fas-ligand activities in activated T cells of kidney transplant recipients.
Nakajima H; Oka T
Transplant Proc; 1997 Sep; 29(6):2533-4. PubMed ID: 9290729
[No Abstract] [Full Text] [Related]
3. CD95L confers immune priviledge to liver grafts which are spontaneously accepted.
Fändrich F; Lin X; Zhu X; Klöppel G; Parwaresch R; Kremer B
Transplant Proc; 1998 Jun; 30(4):1057-8. PubMed ID: 9636427
[No Abstract] [Full Text] [Related]
4. Involvement of Fas and Fas ligand interaction in allogeneic hepatocyte rejection in the spleen.
Kawahara T; Kasai S; Yagita H; Kato K; Sawa M; Nakajima A; Azuma M; Okumura K; Futagawa S; Mito M
Transplant Proc; 1997 Jun; 29(4):2187-8. PubMed ID: 9193582
[No Abstract] [Full Text] [Related]
5. Mechanisms of rejection of nonvascularized grafts: the role of perforin and Fas.
Selvaggi G; Ricordi C; Podack E; Inverardi L
Transplant Proc; 1997 Jun; 29(4):2075-6. PubMed ID: 9193534
[No Abstract] [Full Text] [Related]
6. Fas-ligand: privilege and peril.
Green DR; Ware CF
Proc Natl Acad Sci U S A; 1997 Jun; 94(12):5986-90. PubMed ID: 9177153
[No Abstract] [Full Text] [Related]
7. Fas and the art of lymphocyte maintenance.
Lenardo MJ
J Exp Med; 1996 Mar; 183(3):721-4. PubMed ID: 8642275
[No Abstract] [Full Text] [Related]
8. Immunoregulatory effects of Fas-mediated signalling.
Lynch DH; Alderson MR; Ramsdell F
J Cell Biochem; 1996 Jan; 60(1):39-46. PubMed ID: 8825414
[No Abstract] [Full Text] [Related]
9. Mature T lymphocyte apoptosis in the healthy and diseased immune system.
Zheng L; Fisher G; Combadiere B; Hornung F; Martin D; Pelfrey C; Wang J; Lenardo M
Adv Exp Med Biol; 1996; 406():229-39. PubMed ID: 8910689
[No Abstract] [Full Text] [Related]
10. The Fas/Fas ligand pathway and Bcl-2 regulate T cell responses to model self and foreign antigens.
Van Parijs L; Peterson DA; Abbas AK
Immunity; 1998 Feb; 8(2):265-74. PubMed ID: 9492007
[TBL] [Abstract][Full Text] [Related]
11. Involvement of Fas-Fas ligand interactions in graft rejection.
Martinez OM; Krams SM
Int Rev Immunol; 1999; 18(5-6):527-46. PubMed ID: 10672500
[TBL] [Abstract][Full Text] [Related]
12. Fas and the immunologically underprivileged intestine.
Ma A
Gastroenterology; 1997 Jul; 113(1):345-8. PubMed ID: 9207297
[No Abstract] [Full Text] [Related]
13. Ocular immunosuppressive microenvironment.
Taylor AW
Chem Immunol; 1999; 73():72-89. PubMed ID: 10590575
[No Abstract] [Full Text] [Related]
14. The Fas counterattack: cancer as a site of immune privilege.
O'Connell J; Bennett MW; O'Sullivan GC; Collins JK; Shanahan F
Immunol Today; 1999 Jan; 20(1):46-52. PubMed ID: 10081230
[No Abstract] [Full Text] [Related]
15. T cell receptor ligation triggers novel nonapoptotic cell death pathways that are Fas-independent or Fas-dependent.
Davidson WF; Haudenschild C; Kwon J; Williams MS
J Immunol; 2002 Dec; 169(11):6218-30. PubMed ID: 12444127
[TBL] [Abstract][Full Text] [Related]
16. Fas ligand expression in islets of Langerhans does not confer immune privilege and instead targets them for rapid destruction.
Kang SM; Schneider DB; Lin Z; Hanahan D; Dichek DA; Stock PG; Baekkeskov S
Nat Med; 1997 Jul; 3(7):738-43. PubMed ID: 9212099
[TBL] [Abstract][Full Text] [Related]
17. Regulation of Fas ligand-induced apoptosis by TNF.
Elzey BD; Griffith TS; Herndon JM; Barreiro R; Tschopp J; Ferguson TA
J Immunol; 2001 Sep; 167(6):3049-56. PubMed ID: 11544288
[TBL] [Abstract][Full Text] [Related]
18. Requirement for transforming growth factor beta1 in controlling T cell apoptosis.
Chen W; Jin W; Tian H; Sicurello P; Frank M; Orenstein JM; Wahl SM
J Exp Med; 2001 Aug; 194(4):439-53. PubMed ID: 11514601
[TBL] [Abstract][Full Text] [Related]
19. Gastric cancer cell lines lack Fas ligand (FasL) expression but kill T cells via a FasL independent pathway.
Tinhofer I; Wykypiel H; Marschitz I; Henn T; Greil R
Gut; 2000 May; 46(5):738-40. PubMed ID: 10836854
[No Abstract] [Full Text] [Related]
20. Apoptosis and CD95 ligand in immune privileged sites.
Bellgrau D; Duke RC
Int Rev Immunol; 1999; 18(5-6):547-62. PubMed ID: 10672501
[No Abstract] [Full Text] [Related]
[Next] [New Search]
